Activation of adenosine1 (A1) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats

Neuropharmacology

Volumn 56, Issue 8, 2009, Pages 1082-1087

  Marek, Gerard J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Adenosine; DOI; Glutamate; Head shakes; Medial prefrontal cortex; Phenethylamine hallucinogens

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; CYCLOHEXYLADENOSINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; PHENETHYLAMINE; PSYCHEDELIC AGENT; SEROTONIN 2A AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENERALIZED ANXIETY DISORDER; HEAD TWITCH; MALE; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SEROTONINERGIC NERVE;

ADENOSINE; AMPHETAMINES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; HALLUCINOGENS; HEAD MOVEMENTS; INJECTIONS, INTRAPERITONEAL; LOCOMOTION; MALE; MOTOR ACTIVITY; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A1; SEROTONIN AGONISTS; XANTHINES;

EID: 67349099505     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.03.005     Document Type: Article

References (53)

1. Andine P., Widermark N., Axelsson R., Nyberg G., Olofsson U., Martensson E., and Sandberg M. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J. Pharmacol. Exp. Ther. 290 (1999) 1393-1408
2. 2A receptor antagonist R-(+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J. Pharmacol. Exp. Ther. 327 (2008) 891-897
3. Benneyworth M.A., Xiang Z., Smith R.L., Garcia E.E., Conn P.J., and Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol. 72 (2007) 477-484
4. 3 receptors mediate inhibition of synaptic transmission in rat cortical neurons. Neuropharmacology 40 (2001) 85-95
5. Browne R.G., and Welch W.M. Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists. Science 217 (1982) 1157-1159
6. 1-selective adenosine antagonist 8-cyclopentyl-1,3-diproprylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch. Pharmacol. 335 (1987) 59-63
7. 2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 29 (2004) 1637-1647
8. Cartmell J., Monn J.A., and Schoepp D.D. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 148 (2000) 423-429
9. Cartmell J., Perry K.W., Salhoff C.R., Monn J.A., and Schoepp D.D. The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole3-acetic acid in the medial prefrontal cortex of the freely moving rat. J. Neurochem 75 (2000) 1147-1154
10. Dunayevich E., Erickson J., Levine L., Landbloom R., Schoepp D.D., and Tollefson G.D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33 (2008) 1603-1610
11. Fastbom J., Pazos A., and Palacios J.M. The distribution of adenosine A1 receptors and 5′-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 22 (1987) 813-826
12. Florio C., Prezioso A., Papaioannou A., and Vertua R. Adenosine A1 receptors modulate anxiety in CD1 mice. Psychopharmacology 136 (1998) 311-319
13. Fontanez D.E., and Porter J.T. Adenosine A1 receptors decrease thalamic excitation of inhibitory and excitatory neurons in the barrel cortex. Neuroscience 137 (2006) 1177-1184
14. Fredholm B.B., and Dunwiddie T.V. How does adenosine inhibit transmitter release. Trends Pharmacol. Sci. 9 (1988) 130-134
15. Galici R., Echemendia N.G., Rodriquez A.L., and Conn P.J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 315 (2005) 1181-1187
16. Gewirtz J.C., and Marek G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23 (2000) 569-576
17. 2A receptor-mediated signalling pathways to affect behavior. Neuron 53 (2007) 439-452
18. Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G., Gingrich J.A., Filizola M., Meana J.J., and Sealfon S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452 (2008) 93-97
19. Goodman R.R., Kuhar M.J., Hester L., and Snyder S.H. Adenosine receptors: autoradiographic evidence for their location on axon terminals of excitatory neurons. Science 220 (1983) 967-969
20. 6-cyclopentyladenosine on phencyclidine-induced behavior and expression of the immediate early genes in the discrete brain regions of rats. Mol. Brain Res. 100 (2002) 1-12
21. Heffner T.G., Wiley J.N., Williams A.E., Bruns R.F., Coughenour L.L., and Downs D.A. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology 98 (1989) 31-37
22. 2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviors produced by NMDA receptor antagonism. Psychopharmacology 170 (2003) 309-319
23. Homayoun H., and Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27 (2007) 11496-11500
24. Homayoun H., Jackson M.E., and Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J. Neurophysiol. 93 (2005) 2005
25. Jain N., Kemp N., Adeyemo O., Buchanan P., and Stone T.W. Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmacol. 116 (1995) 2127-2133
26. Jodo E., Suzuki Y., Katayama T., Hoshino H.Y., Takeuchi S., Niwa S.I., and Kayama Y. Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampal-prefrontal pathway. Cereb. Cortex. 15 (2004) 663-669
27. Klodzinska A., Bijak M., Tokarski K., and Pilc A. Group II mGlu receptor agonists inhibit behavioral and electrophysiological effects of DOI in mice. Pharmacol. Biochem. Behav. 73 (2002) 327-332
28. 3H]MDL 100,907. Naunyn Schmiedebergs Arch. Pharmacol. 356 (1997) 446-454
29. Marder S.R. Limitations of dopamine-D2 antagonists and the search for novel antipsychotic strategies. Neuropsychopharmacology 21 S6 (1999) S117-S121
30. Marek G.J., Heffner T.G., Richards J.B., Shaughnessy R.A., Li A.A., and Seiden L.S. Effects of caffeine and PD 116,600 on the differential-reinforcement-of-low rate 72-s (DRL 72-s) schedule of reinforcement. Pharmacol. Biochem. Behav. 45 (1993) 987-990
31. 2A and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 292 (2000) 76-87
32. Marek G.J., Wright R.A., Gewirtz J.C., and Schoepp D.D. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 105 (2001) 379-392
33. Marek G.J., Wright R.A., Johnson B.G., Fell M., Svensson K., Benvenga M., Chaney S., Schoepp D.D., and Monn J. Activation of mGlu2 receptors mediates the "antipsychotic-like" activity of mGlu2/3 receptor agonists in three psychotomimetic drug models and regional distribution of mGlu2 vs. mGlu3 receptors. Neuropharmacology 55 (2008) 608-609
34. Meltzer H.Y., Arvanitis L., Bauer D., Rein W., and Group M.T.S. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorders. Am. J. Psychiatry 161 (2004) 975-984
35. Moghaddam B., and Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonists in rats. Science 281 (1998) 1349-1352
36. Muschamp J.W., Regina M.J., Hull E.M., Winter J.C., and Rabin R.A. Lysergic acid diethylamide and (-)-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex. Brain Res. 1023 (2004) 134-140
37. Ochiishi T., Chen L., Yukawa A., Saitoh Y., Sekino Y., Arai T., Nakata H., and Miyamoto H. Cellular localization of adenosine A1 receptors in rat forebrain: immunohistochemical analysis using adenosine A1 receptor-specific monoclonal antibody. J. Comp. Neurol. 411 (1999) 301-316
38. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., and Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 13 (2007) 1103-1108
39. 1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl aminopropane)-2 (DOI). Neurosci. Lett. 115 (1990) 74-80
40. Rivkees S.A., Price S.L., and Zhou F.C. Immunohistochemical detection of A1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia. Brain Res. 677 (1995) 193-203
41. Rorick-Kehn L.M., Johnson B.G., Knitowski K.M., Salhoff C.R., Witkin J.M., Perry K.W., Griffey K.I., Tizzano J.P., Monn J.A., McKinzie D.L., and Schoepp D.D. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 193 (2007) 121-136
42. 3 adenosine receptor. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 10365-10369
43. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299 (2001) 12-20
44. Scruggs J.L., Schmidt D., and Deutch A.Y. The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neurosci. Lett. 346 (2003) 137-140
45. Shaw E., and Woolley D.W. Some serotoninlike activities of lysergic acid diethylamide. Science 124 (1956) 121-122
46. 6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat. Eur. J. Pharmacol. 369 (1999) 325-329
47. Stutzman G.E., Marek G.J., and Aghajanian G.K. Adenosine preferentially suppresses serotonin2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex. Neuroscience 105 (2001) 55-69
48. Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., and Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16 (1997) 357-372
49. Willins D.L., and Meltzer H.Y. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J. Pharmacol. Exp. Ther. 282 (1997) 699-706
50. Winstanley C.A., Theobald D.E.H., Dalley J.W., Glennon J.C., and Robbins T.W. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology 176 (2004) 376-385
51. Woolley D.W., and Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. U.S.A. 40 (1954) 228-231
52. 1A receptors to the same effector systems in rat hippocampus: biochemical and electrophysiological studies. Mol. Pharmacol. 35 (1989) 484-494
53. Zhai Y., George C.A., Zhai J., Nisenbaum E.S., Johnson M.P., and Nisenbaum L.K. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28 (2003) 45-52